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Abstract
Background: Chronic rhinosinusitis with nasal polyps is a chronic disease frequently seen in otorhinolaryngological
practice. Along with its chronic disease burden it creates high societal costs. Therapy consists of long-term use of
medication and, if insufficient, endoscopic sinus surgery. No consensus exists on the right timing and extent of
disease that warrants surgery. Furthermore, there is lack of clinical knowledge about the benefit of surgery over
medication only. The current trial evaluates the clinical effectiveness and cost-effectiveness of endoscopic sinus
surgery in addition to drug treatment versus medication exclusively in the adult patient group with nasal polyps.
Methods: A prospective, multicentre, superiority, randomised controlled (PolypESS) trial in 238 patients aged 18
years or older selected for primary or revision endoscopic sinus surgery by the otorhinolaryngologist was designed.
Patients will be randomised to either endoscopic sinus surgery in addition to medication or medical therapy only.
Relevant data will be collected prior to randomisation, at baseline and 3, 6, 12, 18 and 24 months after start of
treatment. Complete follow-up will be 24 months. Primary outcome is disease-specific Health-related Quality of Life
quantified by the SNOT-22 after 12-month follow-up. Secondary outcomes are generic Health-related Quality of Life,
cost-effectiveness, objective signs of disease and adverse effects of treatment. Subgroup analyses will be performed
to verify whether treatment effects differ among patient phenotypes.
Discussion: The PolypESS trial will investigate tailored care in adult patients with chronic rhinosinusitis with nasal
polyps and will result in improved clinical pathways to help to determine in which circumstances to perform
surgery.
Trial registration: Dutch Trial Register, NTR4978. Registered on 27 November 2014.
Keywords: Sinusitis, Nasal polyps, Chronic disease, Surgery, Endoscopy, Endoscopic surgical procedure, Drug
therapy, Outcome, Quality of life, Cost-effectiveness analysis
Background
Chronic rhinosinusitis (CRS) can manifest as a disease
with nasal polyps (CRSwNP) or without nasal polyps
(CRSsNP). The prevalence of both forms of CRS in
Europe is around 11% [1]. CRSwNP is the more serious
form of CRS and is associated with a prevalence of 1–4%
[2]. Patients with CRS experience a significant impact on
most aspects of Health-related Quality of Life (HRQOL)
and investigation has shown this to exceed the impact on
HRQOL of patients with chronic heart failure, diabetes
and chronic back pain [3, 4]. The high prevalence and sig-
nificant negative impact on most aspects of HRQOL bur-
dens the diagnostic process and treatment with high
medical resource usage and high societal costs [1].
(Inter-)national clinical CRS guidelines advise starting
drug treatment for at least 1 month before considering
surgery; however, there is no guideline that advises or
specifies conditions that warrant surgery [3, 5, 6]. Currently,
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patients failing drug treatment are offered a more intensive
drug regimen or endoscopic sinus surgery (ESS) in
addition to drug treatment. In The Netherlands most
otorhinolaryngologists prefer surgery, though practice
variance is high with regard to the timing and rationale of
ESS. These differences lead to inefficient health care
practice. Also, if ESS is not proven to be (cost-)effective,
risks are generated in exposing patients to ineffective
treatment.
A national audit in the UK demonstrated that 69% of
ESS is performed for CRSwNP [7]. Corresponding data
in The Netherlands are lacking, but may be expected to
be similar. A recent Chronic Rhinosinusitis Epidemi-
ology Study (CRES) performed in the UK demonstrated
that from all respondents with CRSwNP (N = 651) 57%
underwent previous sinonasal surgery and 20% under-
went multiple surgeries [8]. This high burden of primary
and revision surgery remains unclear in aetiology, but
highlights the need for more research concerning endo-
typing and phenotyping patients with CRSwNP as well
as more research concerning aspects of surgery itself.
A recent analysis of the National Comparative Audit
of Surgery for Nasal Polyposis and Chronic Rhinosinusi-
tis depicted that almost 40% of patients undergoing ESS
suffered more than 5 years from their symptoms related
to CRS [9]. Hopkins et al. specifically looked at the tim-
ing of ESS and its influence on symptoms. In the Na-
tional Comparative Audit of Surgery for Nasal Polyposis
and Chronic Rhinosinusitis [7] the effect of patient time
to surgery on symptomatic outcomes was evaluated and
it was found that patients treated at an early stage in the
course of disease (i.e. within 12 months after first diag-
nosis of CRS) experience more improvement in symp-
toms after surgical intervention compared to patients
treated after a longer burden of CRS (i.e. after 5 years
from first diagnosis of CRS) [9]. On top of this finding,
the cohort of patients treated after a longer period of
CRS had greater CRS-related health care needs postop-
eratively, consisting of medical visits and prescriptions
per patient per year [10]. This available data raises more
questions about the right timing of ESS.
The systematic review of the Cochrane Review Group
on ESS for CRS (2006) concluded, with the limited evi-
dence available, that ESS has not demonstrated an add-
itional benefit in comparison to drug treatment. The
need for more randomised trials was highlighted in the
review [11].
A recent non-randomised, multicentre cohort study by
Smith et al. looked at the differences in HRQOL in a
CRS patient group that self-selected ESS versus a patient
group that self-selected drug treatment. They demon-
strated a significantly better improvement in HRQOL in
addition to less use of systemic medication usage after
ESS in comparison to on-going medication until 6-month
follow-up [12]. They also found a better HRQOL in pa-
tients that self-selected ESS at 1-year follow-up [13].
Scientific evidence for the effectiveness and the sever-
ity of disease that warrants ESS, ideally retrieved from a
well-designed randomised controlled trial, is missing.
The aim of the present trial is to investigate in a rando-
mised fashion whether two regularly applied treatment
strategies used in adult patients with CRSwNP, ESS in
addition to drug treatment or drug treatment only, differ
in generic and disease-specific HRQOL and to establish
the presumed superiority of ESS. A comparison with re-
spect to cost-effectiveness will also be made.
Methods
Study objectives
The primary aim of the PolypESS trial is to assess the ef-
fectiveness of ESS in addition to drug treatment as com-
pared to drug treatment alone in adults with CRSwNP
in terms of improving patients’ HRQOL, measured by
the Sinonasal Outcome Test 22 (SNOT-22) at 12-month
follow-up. Key secondary aims of the trial are evaluation
of the effectiveness of ESS in addition to drug treatment
as compared to drug treatment alone in the short (3–6
months) and long (12–24 months) term, in terms of
generic HRQOL, objective signs of disease and adverse
effects of treatment. This trial will also evaluate which
patient phenotypes within CRSwNP benefit from ESS in
addition to drug treatment as compared to drug treat-
ment alone. Furthermore, the relation between health
care resource use and patient costs and effects of ESS
will be determined from a societal point of view. It is
hypothesised that a more tailored approach for patients
with CRSwNP will be associated with lower medical and
indirect costs (health care utilisation and productivity loss).
Study design
The PolypESS is an investigator-initiated, prospective,
open, national, multicentre randomised controlled trial
investigating the (cost-)effectiveness of ESS in patients
suffering from CRSwNP. Suitable patients will be rando-
mised into two treatment groups. In the first group pa-
tients will undergo ESS in addition to medication, in the
second group patients will receive an intensified drug
treatment only. Total follow-up is 24 months for all in-
cluded consecutive patients. Otorhinolaryngologists in
the participating centres are asked to recruit patients.
Any patient who meets the inclusion criteria (described
in detail below in ‘Study population’ section) will be
informed about the trial and asked to participate.
The coordinating trial centre (Academic Medical Centre,
Amsterdam, The Netherlands) will contact patients who
have expressed interest in the trial. The study team mem-
ber will provide detailed written and oral information
about the trial and answer any questions. If patients agree
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to participate, inclusion and exclusion criteria will be
checked and a baseline visit will be scheduled. Potential
participants have sufficient time before they give their final
consent to participate in the trial. If patients decline
participation, known clinical data on disease-specific
HRQOL and objective signs of disease are used to
evaluate whether the findings of the consecutive sam-
pling are generalisable to the target population. The
trial reporting is according to the CONsolidated Stan-
dards of Reporting Trials (CONSORT) guidelines and
the CONSORT extension for nonpharmacological inter-
ventions (Fig. 1) [14, 15]. The Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) 2013
Checklist: ‘Recommended items to address in a clinical
trial protocol and related documents’, can be found in
Additional file 1. The SPIRIT participant schedule is
shown in Table 1.
Setting
The trial is performed in 15 hospitals, three university-
affiliated hospitals (The Academic Medical Centre,
Amsterdam; Erasmus Medical Centre, Rotterdam; VU
Medical Centre, Amsterdam) and teaching hospitals
(Amstelland Hospital, Amstelveen; Alrijne Hospital, Lei-
derdorp and Alphen aan den Rijn; BovenIJ Hospital,
Amsterdam; Deventer Hospital, Deventer; Flevo Hos-
pital, Almere; Haga Hospital, Den Haag; Onze Lieve
Vrouwe Gasthuis location East, Amsterdam; Onze Lieve
Vrouwe Gasthuis location West, Amsterdam; Spaarne
Hospital, Hoofddorp; Spaarne Hospital, Haarlem;
Tergooi Hospital, Hilversum and Blaricum; and Westfries
Gasthuis, Hoorn) in The Netherlands. The same medical
researcher and research nurses perform all trial assess-
ments in the participating centres, apart from nasal endos-
copy. Nasal endoscopy is performed by the local ENT
surgeon as part of standard care.
Study population
Adult patients (18 years of age or older) with bilateral
CRSwNP who have been selected by their ENT sur-
geon as candidates for primary or revision ESS are
eligible for participation. If patients are excluded from
participation, reason(s) for exclusion are registered. Ex-
clusion criteria include the presence of systemic diseases
affecting the nose (e.g. Wegener’s granulomatosis, sar-
coidosis, primary ciliary dyskinesia, cystic fibrosis),
antrochoanal polyps, malignant polyps, inverted papil-
loma, sinonasal tumours, absolute need for surgical ther-
apy, contraindications for surgical therapy, need for
radical surgery (Draf III, Denker surgery, medial
Fig. 1 CONsolidated Standards of Reporting Trials (CONSORT) flow diagram of PolypESS study (ESS, endoscopic sinus surgery)
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maxillectomy), polypectomy without ethmoidectomy,
continuous use of systemic corticosteroids for diseases
other than CRSwNP, continuous medication for other
diseases influencing CRSwNP (e.g. other immunosup-
pressive drugs), pregnancy at enrolment, mental or sys-
temic illnesses preventing adequate participation in the
trial and any other scheduled surgical intervention pre-
venting adequate participation in the trial. Furthermore,
potential participants are not allowed to have used any
systemic corticosteroids in the previous 4 weeks before
enrolment and they should not have suffered from an
acute upper or lower respiratory tract infection at the
time of enrolment or during the previous 2 weeks.
Patient enrolment
Selection of patients follows a two-stage procedure.
Consecutive patients are screened for eligibility by a
recruiting local otorhinolaryngologist in the outpatient
department. Additionally a telephone interview is sched-
uled by the medical researcher in the Academic Medical
Centre during which eligibility will be reassessed. Pa-
tients will be enrolled by the medical researcher during
a clinic visit in the concerning hospital. Patients meeting
all inclusion criteria and no exclusion criteria can be in-
cluded and will be randomly assigned, after informed
consent is given.
Baseline measurements
On the day of enrolment, patients will undergo the same
HRQOL and objective evaluation, including the SNOT-
22, the EuroQol-5D-5L questionnaire (EQ-5D-5L, the
EuroQol Group) and nasal endoscopy, that will be used
after treatment (see “Outcomes” section). Clinical data is
collected by the enrolling medical researcher and focuses
Table 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule patient enrolment, interventions and
assessments
Visit -2 Visit -1 Visit
0















ENT-surgeons asks patient to participate x
Informed Consent x
Demographic Data x




ESS or intensify medical treatment based on
randomisation
x
Vital Signs and bodyweight x
Symptoms x x x x x x
Disease specific HRQOL and symptoms (SNOT-22) x x x x x x
Generic HRQOL (EQ-5D-5L) x x x x x x
Endoscopic assessment of the nose x x x x x
Olfactory function (Sniffin’ Sticks) x x x x x
Nasal obstruction (PNIF) x x x x x
Daily records cards (DRC) x x x x x x
CRS disease control x x x x x
Asthma control x x x x x x
Healthcare resource use x x x x x
Adverse effects x x x x x
CT scan (Lund-Mackay score) x
Surgical report x
Laboratory tests, pregnancy test x
Skin Prick test (if done in the last year, results are
recorded)
x
Wks weeks, HRQOL health-related quality of life, SNOT-22 sinonasal outcome test 22, EQ-5D-5L EuroQol-5D-5L questionnaire, PNIF peak nasal inspiratory flow
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on the (severity of ) patient-reported symptoms, previous
clinical examinations, previous sinonasal surgery, previ-
ous conservative treatment and complete medical his-
tory. Demographic variables include age, gender,
ethnicity, marital status, family situation and highest
level of education. Additional study information includes
the presence or absence of asthma, acetylsalicylic acid
(ASA) intolerance, allergy, occupational exposure, smok-
ing habits and alcohol consumption. Objective measure-
ments recorded are baseline height, weight, blood
pressure, resting heart rate, total IgE, serum eosinophil
level and computed tomography (CT) scores using the
Lund-Mackay scoring system. This system uses a 0–1–2
score dependent upon absent, partial or complete opaci-
fication, respectively, of each individual sinus and the
ostiomeatal complex, contributing to a maximum score
of 12 per side. The total score of the two sides can reach
a maximal 24 points [16]. A urine pregnancy test will be
performed in female patients with childbearing potential
if in doubt of pregnancy.
Skin Prick Test
To assess allergic sensitisation, the Global Allergy and
Asthma European Network’s (GA2LEN) standardised
method of the Skin Prick Test (SPT) is used [17].
Patients are instructed to stop taking antihistamine
medication 5 days before the SPT. A positive reaction to
the SPT is defined as a skin reaction larger than 3 mm
for one or more of the tested allergens (at least tree, grass,
Dermatophagoides pteronyssinus, cat, dog, moulds) and
no reaction to the negative control.
Interventions
Patients will be assigned to a surgical strategy (ESS in
addition to drug treatment) or a drug treatment strategy
exclusively. Clinicians and patients will not be blinded to
the treatment arm of the study. Those assigned to sur-
gery will be offered ESS within 6 weeks of randomisa-
tion. Those assigned to drug treatment will be seen by
the otorhinolaryngologist within 6 weeks of randomisa-
tion to define the need for additional medication. As this
is a pragmatic trial, ESS refers to the surgery performed
regularly by otorhinolaryngologists in The Netherlands.
The extent of surgery is tailored to the extent of the




The effectiveness of both interventions is evaluated by
the SNOT-22 after 12 months of follow-up. The SNOT-
22 is a patient-reported measure of outcome (PROM)
consisting of 22 individual custom-designed questions for
use in CRS with or without nasal polyposis. The SNOT-22
covers a broad range of disease-specific HRQOL topics
including physical complaints, functional limitations and
emotional consequences. This questionnaire has shown to
be reliable and valid in clinical practice to assess the
impact of CRS on a patient’s disease-specific HRQOL and
to measure treatment-related changes [18].
Secondary study outcomes
Clinical outcome data will be collected at 3, 6, 12, 18
and 24 months after start of treatment. All measure-
ments are performed by an adequately trained medical
researcher and research nurses. All measurements are
carried out according to protocol procedures and de-
fined standard operating procedures.
HRQOL measurements
To assess generic HRQOL the EQ-5D-5L is administered
[19]. The questionnaire comprises five domains/questions:
mobility, self-care, usual activities, pain or discomfort and
anxiety or depression. An EQ-5D-5L index can be calcu-
lated and quantifies a participant’s health status on a scale
ranging from 0 (very bad health) to 1 (perfect health).
Patients are also instructed to rate their overall generic
HRQOL using a Visual Analogue Scale (EuroQol-5D VAS)
ranging from 0 (very bad health) to 100 (perfect health). In
this study the validated Dutch translation is used.
Symptoms
Total clinical symptoms, symptoms of rhinorrhoea, facial
pain/headache, loss of smell and nasal blockage are mea-
sured with a Visual Analogue Scale (VAS) ranging from
0 (no problem) to 10 (worst imaginable problem).
Olfactory function
The ‘Sniffin’ Sticks Identification Test is used to assess
olfactory performance. These twelve sticks are odour-
dispensing devices that resemble felt-tipped pens and
are held under the participant’s nose for 3–4 s. The par-
ticipant must make a forced choice from a list of four
options as to the nature of the odour. The score corre-
sponds to the amount of correct answers.
Nasal obstruction
The peak nasal inspiratory flow (PNIF) method is used
to quantify nasal obstruction. A portable Youlten Peak
Flow Meter (Clement Clarke International) is used. After
applying a ventilation mask to firmly cover the nose and
the mouth, participants are instructed to inhale as
strongly as possible through the nose with the mouth
closed. Three maximal inspirations are performed and
the highest value (L/min) is used for analysis.
Endoscopic nasal assessment
Three different nasendoscopic measurements are used:
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1. The Meltzer Clinical Scoring System is a 0–4 polyp
grading system (0 = no polyps, 1 = polyps confined to
the middle meatus, 2 = multiple polyps occupying
the middle meatus, 3 = polyps extending beyond
middle meatus, 4 = polyps completely obstructing
the nasal cavity)
2. The Modified Lund-Kennedy Endoscopy Score is a
0–2 scoring system in which the endoscopic appear-
ances of both nasal fossae are rated for polyps, oedema
and discharge (polyps: 0 = no polyps, 1 = polyps con-
fined to the middle meatus, 2 = polyps beyond the
middle meatus; oedema: 0 = no oedema, 1 =mild
oedema, 2 = severe oedema; discharge: 0 = none, 1 =
clear and thin, 2 = thick and eosinophilic) [20]
3. The Modified Lund-Mackay Postoperative Endos-
copy Score (MLMES) applies to all participants who
previously underwent sinus surgery. The endoscopic
appearances of all ten cavities (left and right maxil-
lary, ethmoid, sphenoid and frontal sinuses and ol-
factory fossa) are quantified for mucosal
inflammation (0–6: 0 = normal mucosa, 1 = mild
oedematous mucosa with patent cavity, 2 = severely
oedematous mucosa with compromised cavity, 3 =
mild polypoid mucosa with patent cavity, 4 = severe
polypoid mucosa with compromised cavity, 5 = polyp
confined within cavity, 6 = polyp extending beyond
cavity), mucus (0–2: 0 = none, 1 = clear and thin, 2 =
thick and eosinophilic) and purulent discharge (0–2:
0 = absent, 2 = present). This system produces a
score of 0–100. Draf III cavities are scored as two
frontal sinuses separately. Nonpneumatised sinuses
and nondiseased sinuses that have not undergone
surgery are scored as 0. The olfactory fossa is evalu-
ated by assessing the cleft between the nasal septum
and the middle turbinate anteriorly and the superior
turbinate posteriorly [21].
CRS disease control
Disease control will be evaluated as suggested by the
European Position Paper on Chronic Rhinosinusitis
(EPOS 2012) (see Additional file 2). Nasal blockage, rhi-
norrhoea/postnasal drip, facial pain/headache, olfactory
function, sleep disturbance or fatigue, nasendoscopy and
systemic medication needed to control disease are evalu-
ated. Each characteristic is rated as currently controlled
or partly controlled, contributing to a general conclusion
of CRS being controlled, partly controlled or uncon-
trolled at the time of assessment [3].
Asthma control
As asthma is a common comorbid condition in patients
with CRSwNP, the Asthma Control Test (2002 TM
QualityMetric Incorporated) is used in the subpopulation
of patients with asthma. This validated appraisement
contains five individual questions to assess asthma disease
control.
Diaries
Participants are instructed to complete a diary 2 weeks
before a follow-up visit until 2 weeks after a follow-up
visit. Daily nasal symptoms and medication compliance
will be recorded. The diary is also suitable to record
symptomatic exacerbations, other medical problems and
adverse effects or events. The nasal symptom scores,
used to evaluate efficacy as a measure of compliance,
will be calculated from the daily subject-rated scores of
four nasal symptoms: headache/facial pain, rhinorrhoea,
nasal congestion and loss of smell. Severity of symptoms
is scored on a 0 to 3 scale; 0 = none (symptom is not
present), 1 =mild (sign/symptom is clearly present but
minimal awareness; easily tolerated), 2 =moderate (def-
inite awareness of sign/symptom that is bothersome but
tolerable), 3 = severe (sign/symptom is hard to tolerate;
causes interference with activities of daily living and/or
sleeping). Subjects will be instructed to score and docu-
ment their symptoms every 24 h in a reflective manner
using the (electronic) diary.
Exacerbations and adverse effects
Medical files and patient diaries are used to record any
unwanted side effects and readmissions during the study
period. Participants are actively queried every follow-up
visit as to whether they experienced any complications
or adverse effects.
Health care resource use and costs
Resource use and costs of health care utilisation, out-of-
pocket expenses and lost productivity are retrieved from
hospital databases, financial reports, medical files, pa-
tient diaries and a modified version of the Erasmus
iMTA ‘Productivity Cost Questionnaire’ and modified
iMTA ‘Medical Consumption Questionnaire’ [22, 23].
Data collection, management and storage
Source documents are a custom-designed paper Case
Report Form and patient medical files. In addition, elec-
tronic questionnaires are used whenever possible (Lime-
survey®). All VAS questionnaires are carried out on
paper. The electronic diary is compatible across all
browsers (https://kno-polypess.minddistrict.nl), smart-
phones and tablet devices (Minddistrict® application).
Participants receive a personal username and create a
password. If electronic device utilisation is not feasible,
paper diaries are administered.
Clinical data will be stored in a custom-designed,
password-protected study database (OpenClinica® soft-
ware). Paper Case Report Forms, paper questionnaires
and signed informed consents are stored in locked
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cabinets. A Data Monitoring Committee is allowed to
access the collected clinical data mother file, wherein no
identifiable patient data is stored; unique patient identifi-
cation codes are used instead.
Sample size
PolypESS is a superiority trial in which disease-specific
HRQOL, measured with the SNOT-22 at 12-month
follow-up, is the primary outcome of interest. The sam-
ple size calculation is build on the literature-based
assumption that the minimal clinically important differ-
ence (MCID) for SNOT-22 is 8.9 points (SD 20.0) [18].
Using a 5% significance level and a power of 90% yields
a sample size of 238 patients, which includes a 10%
anticipated loss to follow-up.
Randomisation
A randomisation sequence is generated using block sizes
of 6 stratified by study centre. A central, password-
protected, consistently available automated randomisa-
tion system (ALEA® software, Trans European Network
for clinical trial services (TenALEA) consortium,
Amsterdam, The Netherlands) has been developed by
the independent Clinical Research Unit in the Academic
Medical Centre, Amsterdam, The Netherlands. Due to




Results will be based on the intention-to-treat method.
In addition, per-protocol analysis, including only pa-
tients who adhered completely to the clinical trial in-
structions and treatment specified in the protocol, will
also be performed to check the robustness of results.
Continuous normally distributed variables will be
expressed by their mean and standard deviation or, when
not normally distributed, as medians and their interquar-
tile ranges. Categorical variables will be expressed as
counts (n) and percentages (%). Effects on HRQOL,
nasal endoscopy and symptom score will be calculated
as mean differences with 95% confidence intervals.
HRQOL, short- and long-term effects will be addition-
ally evaluated at 3, 6, 12, 18 and 24 months’ follow-up,
respectively. It is expected that randomisation will bal-
ance patients’ baseline characteristics. However, if imbal-
ances occur between groups that are related to possible
effect modification, subgroup analyses will be performed
according to the indication for surgery.
A further detailed statistical analysis plan will be devel-
oped and reported by the chief investigators prior to the
database being locked at the end of follow-up for final
analysis.
Cost-effectiveness analysis (CEA)
General considerations Alongside the randomised clin-
ical trial an economic study will be performed. The eco-
nomic evaluation will be set up as a cost-effectiveness
analysis (CEA). The CEA focuses on the possible gained
benefits of ESS in addition to drug treatment versus
drug treatment alone and the related health care costs.
The economic evaluation will be performed from a soci-
etal point of view.
Patient outcomes The SNOT-22 will be measured to
evaluate impact of both treatments. This will be used as
endpoint in the economic evaluation. The cost-
effectiveness of the interventions will be compared by
assessing cost per Quality-adjusted Life Year (QALY),
calculated from the health utility scores obtained with
the EQ-5D-5L.
Cost analysis Costs will be primarily assessed by the
intervention study (and not the additional costs of
underlying comorbid diseases). The time horizon of this
cost analysis will be limited to 12-month follow-up.
With this time horizon no discounting of costs and ef-
fects will be performed. The societal perspective cap-
tures the value of all resources used. Costs associated
with treatment from a long-term perspective will be esti-
mated and incorporated in a scenario analysis. Subgroup
analyses will be done. Overall costs will be compared
across the treatment groups and, where relevant, differ-
ences will be calculated, inclusive of 95% confidence in-
tervals. Incremental cost-effectiveness ratios (iCERs) will
be calculated.
Measurements The prospective cost evaluation will pri-
marily focus on health care utilisation (direct medical
costs), travel expenses (direct nonmedical costs) and lost
productivity (indirect costs) due to absence from work
or decreased performance at work (productivity loss).
The direct medical costs include the costs of all proce-
dures associated with both treatment strategies (e.g. doc-
tor’s visits, medication, hospital admissions and surgical
interventions, sinus CT, endoscopy and exacerbations).
Out-of-pocket expenses include additional over-the-
counter drugs and travel costs. Additional costs as a
result of comorbid conditions (e.g. asthma) will be
excluded.
In the base case analysis, indirect costs (based on lost
productivity) will be calculated using the friction cost
method. Productivity losses will be estimated based on
data concerning absence from work. Health service re-
source use and costs of both treatment strategies will be
measured from a health service and societal perspective.
Protocol-driven costs will be excluded.
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Unit costs Costs are defined as the volumes of used re-
sources multiplied by calculated unit prices. For the
valuation of health care utilisation, standard prices pub-
lished in the Dutch costing guidelines and market prices
will be used [24]. Standard guideline prices will be used
for all diagnostic interventions, hospital admissions,
post-operative care, outpatient visits and travelling.
Statistical analysis As most volumes of resource utilisa-
tion follow a skewed distribution, differences between
the two groups will be statistically evaluated with bias-
corrected bootstrap analysis. An iCER will be calculated,
with the observed HRQOL as effect parameter.
The economic analysis will be expanded with a
scenario-analysis to extrapolate the consequences of im-
plementation and actual performance of the screening
strategy in the targeted population. In sensitivity analysis
the validity of the developed scenarios is evaluated. Un-
certainty will be addressed by means of bootstrapping.
Budget impact analysis (BIA)
General considerations In addition to the assessment
of cost-effectiveness, a budget impact analysis (BIA) will
be performed to determine the potential financial impact
of more tailored treatment for patients with CRSwNP
on national total health care costs in the future. The
analysis will be performed according to the ISPOR Task
Force guidelines [25]. The BIA will be conducted from
the viewpoint of the publicly funded health and social
care system. No discounting will be applied, tariffs and
prices will be held constant over the years.
Cost analysis
The BIA will be based on clinical data that reflect the
size and characteristics of the population, the current
treatment mix, the effectiveness of ESS, and the resource
use and costs for ESS (surgery, post-operative care, exac-
erbations and reinterventions).
Monitoring, safety and reporting of adverse events
An independent Good Clinical Practice (GCP)-certified
Monitoring Committee has been established. Members
of the independent Clinical Research Unit of the Aca-
demic Medical Centre will perform monitoring and it
will be conducted according to International Conference
on Harmonisation (ICH)-GCP guidelines. A detailed
study-specific monitor plan (version 3, 1 August 2016)
has been formulated. The monitor plan is designed to
verify that the rights and wellbeing of the participants is
protected, that the reported trial data are accurate,
complete and verifiable from the source documents and
that the conduct of the trial is in compliance with the
currently approved protocol, GCP and applicable regula-
tory requirements. Every participating site will be
physically visited at least once during the study period.
All other monitoring activities will be centralised to de-
tect sources of data irregularities, by exploring the clin-
ical trial database. The monitoring plan will be updated
and revised as needed.
The risk of the current trial is estimated to be low. Pa-
tients will only be asked to participate if there is an indica-
tion for surgery as decided by their otorhinolaryngologist.
The surgery performed and the medication prescribed is
according to standard of care in patients with CRSwNP.
Written informed consent is obtained from every partici-
pant. The patient is free to withdraw from the study at
any time. Collected clinical data will be anonymised with
unique patient identification codes.
Adverse events (AEs) to be reported are complications
after SPT, ESS and adverse effects from any drug treat-
ment started for CRSwNP. All study-specific AEs re-
ported spontaneously by the participant or observed by
the investigators will be recorded each visit. At every
follow-up visit or interim telephone contact the investi-
gators should inquire about AEs by asking the patients
and by actively screening the patient’s medical file. Ser-
ious adverse events (SAEs) possibly related to the study
procedure will be reported to the principal investigator
within 24 h. The local investigator informs the study coord-
inator in the Academic Medical Centre and is responsible
for reporting SAEs annually to the accredited Medical Eth-
ics Committee that approved the protocol in a line-listing
format combined with the annual progress report.
In case of life-threatening SAEs or death, reporting to
the accredited Medical Ethics Committee will occur not
later than 7 days after the study coordinator’s knowledge
of the event.
Dissemination
Presentations at (inter)national scientific conferences
will be part of dissemination. Results will also be pub-
lished in scientific journals. The raw trial data will be
made available to the members of the Dutch Society of
Otorhinolaryngology and Head and Neck Surgery.
Discussion
The timing and indications for ESS in the management
of CRSwNP/CRSsNP are mainly based on practitioners’
knowledge. National and international clinical guidelines
advise to start with drug treatment for at least 1 month
before considering surgical treatment. Based on clinical
findings patients start a drug treatment consisting of
nasal corticosteroids, eventually supplemented with a
short course of systemic corticosteroids or a longer
course of antibiotics [3, 5, 6, 26–28]. Patients failing drug
treatment are offered a choice between more intensive
drug treatment and surgery in addition to drug treatment.
Shared decision-making between the otorhinolaryngologist
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and the patient decides the moment that surgery is needed
for relief of symptoms. Because of the chronic nature of
the (mucosal) disease, the optimal treatment would be
local treatment with medication combined with surgery.
Rudmik et al. have already shown in a Markov
decision-tree economic evaluation that ESS would be
the most cost-effective intervention compared to contin-
ued medical therapy from a long-term perspective, at
least with 74% certainty [29]. Limitation of this study,
however, is that this economic evaluation was not per-
formed alongside a RCT. The current study will be the
first high-quality multicentre RCT (N = 238) to evaluate
the role of ESS and to assess the cost-effectiveness of
ESS in addition to drug treatment compared to drug
treatment alone in adults with CRSwNP.
Currently, this trial is being conducted in 15 hospi-
tals in The Netherlands. To the best knowledge of
the investigators no other randomised studies to
evaluate the same question are currently being per-
formed. The objective is to demonstrate a higher
HRQOL after ESS compared to drug treatment only
in the treatment of CRSwNP. The outcome measure-
ments are chosen according to experience in the field.
Patient symptoms are thought to be an important
parameter because patients seek medical advice in
case of symptoms, regardless of the extent of disease
visible on nasal imaging or with nasendoscopy. The
usage of PROMs in clinical trials is growing and
HRQOL is a frequently used clinical endpoint in clinical
trials for CRS.
After the two-arm randomisation process, the medical
intervention consists of any drug treatment that can
be given to patients with CRSwNP in routine medical
practice. The drug treatment purposefully is not stan-
dardised so as to stay closest to standard care. Also,
patients’ need for drug treatment varies with time
and extent of disease. Naturally, this design enhances
diversity; however, it also enhances generalisation of
the results in the real-world situation. Surgical inter-
vention consists of ESS, which is described as any
surgery performed regularly by the otorhinolaryngolo-
gists in The Netherlands. The extent of the surgery is
tailored to the extent of disease. This introduces a
performance bias; however, this will also be closest to
normal care.
The results of this RCT are intended to create a tai-
lored strategy and selective use of ESS in CRSwNP pa-
tients. The results will be generalised to the Dutch
situation and implemented in clinical guidelines.
Trial status
The study is currently in the first phase of patient recruit-
ment and inclusion in 15 Dutch hospitals. Enrolment
started on 13 February 2015. The anticipated recruitment
completion is Summer 2017.
Additional files
Additional file 1: Table S1. SPIRIT 2013 Checklist: recommended items
to address in a clinical trial protocol and related documents. (DOC 122 kb)
Additional file 2: Table S2. Assessment of current clinical control of
chronic rhinosinusitis (CRS) (in the last month), EPOS 2012. (JPG 76 kb)
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